PharmAla Issues Audited Year End 2025 and Unaudited Q1 Fiscal 2026 Financial Statements Life Science Investing
Cizzle Brands Corporation Announces Closing of Transformative Transaction with the Acquisition of Flow Water Inc.'s Co-Manufacturing Business Biotech Investing
Repare Therapeutics Announces Acquisition of Pol? ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration Life Science Investing
Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4 Life Science Investing
Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4 Life Science Investing
